Therapies for Solid Tumors: Pipelines, Markets, and Business Considerations

NEW YORK, Nov. 1, 2012 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

Therapies for Solid Tumors: Pipelines, Markets, and Business Considerations

http://www.reportlinker.com/p01022411/Therapies-for-Solid-Tumors-Pipelines-Markets-and-Business-Considerations.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Pathology

As our understanding of cancer has progressed, newer therapies, such as various targeted therapies and immunotherapy, have become an important part of today's cancer treatment regimens. This report focuses on pharmacological therapies–in particular, the pipelines of emerging drugs—for treatment of solid tumors, discussing:

• The various types of solid tumors that are the focus of the most pharmacological effort, including information about the specific disease, its incidence and epidemiology, current treatment options, and R&D challenges.

• Pipelines of emerging targeted therapies for treatment of solid tumors, organized by pathway or category.

• Business and strategic considerations relating to pharmacological therapy for solid tumors, including discussions of the current and projected markets, and market trends.

• Major challenges and hurdles for companies developing solid tumor therapies.

• Interviews with experts in the field of solid tumors, which were conducted exclusively for this report.

Cancer is not a single disease, but includes many different diseases that are all characterized by the uncontrolled growth and spread of abnormal cells. Within the broad categories of cancer (such as breast or lung cancer), there are many different types. And, even within one type of cancer, the molecular changes that caused the cancer vary with different tumors.

Therapies for Solid Tumors: Pipelines, Markets, and Business Considerations discusses selected major solid tumors that represent the greatest effort by companies developing new therapies for solid tumors. This report begins with an initial focus on pharmacological treatment options currently used for the major solid tumors. While chemotherapy drugs have been used for several decades, more recently, targeted small-molecule drugs and biological therapies including monoclonal antibodies have been introduced. This early chapter discusses all of these therapies.

The major focus of Therapies for Solid Tumors: Pipelines, Markets, and Business Considerations is on pipelines of emerging drugs for treatment of solid tumors. Over 80 therapies that have reached Phase III development are profiled in the body of this report. However, these novel late-stage therapies only represent the "tip of the iceberg" of new therapies being developed for treatment of solid tumors. Information regarding emerging therapies in Phase II or earlier stages of development, plus certain additional Phase III candidates, is presented in tables. More than 530 companies developing more than 1,330 new therapies for solid tumors are included in this report.

Biopharmaceutical companies are exploiting hundreds of potential targets or therapeutic approaches for development of new cancer therapies. The more than 1,330 potential new therapies discussed in this Insight Pharma Report work by a wide range of mechanisms. Many of these emerging cancer therapies have multiple mechanisms of action, and are therefore included in multiple tables within this report.

Therapies for Solid Tumors: Pipelines, Markets, and Business Considerations discusses business strategies relating to development of pharmacological therapies for solid tumors. This includes an analysis of the current market and the potential markets for emerging therapies. Also discussed are major challenges and other tactical considerations for companies working in this space. This Insight Pharma Report concludes with expert interviews with some of these companies.

About the Author

Lucy J. Sannes, PhD, MBA, is president of Sannes & Associates, a consulting firm specializing in evaluation and management of the biosciences. Before forming Sannes & Associates, she held management positions at Genetic Systems and Abbott Laboratories in product development, product support, and technical marketing. Dr. Sannes received her PhD in biological chemistry from the University of Michigan and her MBA from Seattle Pacific University.

Executive Summary

Chapter 1

Introduction

Scope of the Report

Chapter 2

Review of Selected Major Solid Tumors Targeted by Pharmaceutical Companies

2.1. Brain Cancer

2.2. Breast Cancer

2.3. Cervical Cancer

2.4. Colorectal Cancer

2.5. Head and Neck Cancer

2.6. Lung CancerNon–Small-Cell Lung Cancer

Small-Cell Lung Cancer

2.7. Melanoma

2.8. Ovarian Cancer

2.9. Pancreatic Cancer

2.10. Prostate Cancer

2.11. Renal Cancer

Chapter 3

Current Pharmacological Treatment Options for Solid Tumors

3.1. Brain Cancer

3.2. Breast CancerChemotherapy

Hormone Therapy

Targeted Therapy: HER2-Positive Cancers

3.3. Cervical Cancer

3.4. Colorectal CancerChemotherapy

Targeted Therapy: EGF Receptor

Targeted Therapy: VEGF Receptor

3.5. Head and Neck Cancer

3.6. Lung CancerNon–Small-Cell Lung Cancer

Chemotherapy

Kinase Inhibitors

Angiogenesis Inhibitor

Photodynamic Therapy

Small-Cell Lung Cancer

3.7. Melanoma

3.8. Ovarian Cancer

3.9. Pancreatic CancerChemotherapy

Kinase Inhibitors

3.10. Prostate CancerLuteinizing Hormone-Releasing Hormone (LHRH) Agonists

Luteinizing Hormone-Releasing Hormone (LHRH) Antagonists

Antiandrogens

Androgen Synthesis Inhibitor

Chemotherapy

Immunotherapy

3.11. Renal CancerImmunotherapy

Kinase Inhibitors

Vascular Endothelial Growth Factor (VEGF) Inhibitor

3.12. Other Cancers

Chapter 4

Selected Emerging Targeted Therapies That Block Cell Growth, Cell Cycle and Replication, DNA Repair, Cell Proliferation, Tumor Invasion, and Metastasis

4.1. Selected Inhibitors of the EGF Receptor Tyrosine Kinase FamilyBoehringer Ingelheim's Afatinib

CIMAB's, YM Biosciences', and Others' Nimotuzumab

Eli Lilly's and Bristol-Myers Squibb's Necitumumab

Kadmon's KD019

Pfizer's Dacomitinib

Roche/Genentech's PERJETA (Pertuzumab) – Approved June 2012

Roche/Genentech's Trastuzumab Emtansine

4.2. Selected Inhibitors of the Ras-Raf-MEK-ERK PathwayGlaxoSmithKline's Dabrafenib

GlaxoSmithKline's Trametinib

4.3. Selected Inhibitors of c-MetArQule's, Daiichi Sankyo's, and Kyowa Hakko Kirin's Tivantinib

Exelixis' Cabozantinib

Roche/Genentech's Onartuzumab

4.4. Selected Inhibitors of Insulin-like Growth Factor (IGF) and Insulin-like Growth Factor Type 1 Receptor (IGF1R)Amgen's and Takeda Pharmaceutical's Ganitumab

Astellas Pharma's Linsitinib

4.5. Selected TGF-?2 InhibitorsAntisense Pharma's Trabedersen

4.6. Selected Kit and PDGFR InhibitorsAB Science's Masitinib

4.7. Selected PARP (Poly [ADP-Ribose] Polymerase) InhibitorsSanofi's Iniparib

4.8. Selected Inhibitors of the PI3K-Akt-mTOR PathwayMerck's and ARIAD Pharmaceuticals' Ridaforolimus

4.9. Other Emerging Therapies with Antiproliferative EffectsPolaris Group's ADI-PEG 20

Roche/Genentech's Erivedge – Approved January 2012

Chapter 5

Selected Emerging Therapies That Induce Apoptosis

Onconova Therapeutics' Estybon (Rigosertib)

Chapter 6

Selected Emerging Angiogenesis Inhibitors and Vascular-Targeting Agents

6.1. Selected Angiogenesis Inhibitors That Target VEGFR, PDGFR, and/or FGFRAbbott's Linifanib

Advenchen Laboratories', LSK BioPartners', and Jiangsu Hengrui Medicine's Apatinib

Amgen's and Takeda Pharmaceutical's Motesanib (AMG 706)

Astellas Pharma's, AVEO Oncology's, and Kyowa Hakko Kirin's Tivozanib

Bayer HealthCare's Regorafenib

Boehringer Ingelheim's Nintedanib

Bristol-Myers Squibb's Brivanib

Eisai's Lenvatinib

Eli Lilly's Ramucirumab

Novartis' Dovitinib

Pfizer's Inlyta (Axitinib; Approved January 2012)

Sanofi's and Regeneron's Zaltrap (Aflibercept)

Taiho Pharmaceutical's Orantinib

6.2. Selected Angiogenesis Inhibitors That Target TIE Receptor and/or Its LigandsAmgen's and Takeda Pharmaceutical's AMG 386

6.3. Selected Integrin InhibitorsMerck Serono's Cilengitide

6.4. Selected Other Angiogenesis InhibitorsActive Biotech's and Ipsen's Tasquinimod

Medigen Biotechnology's PI-88

6.5. Selected Vascular Targeting/Disrupting AgentsMolMed's NGR-hTNF

Sanofi's Ombrabulin

Chapter 7

Selected Emerging Therapies That Target Hormone Regulation

7.1. Selected Emerging Therapies with Anti-Androgen ActivityAstellas Pharma's and Medivation's Enzalutamide

Millennium: The Takeda Oncology Company's Orteronel

7.2. Selected Other Emerging Therapies Targeting Regulation of HormonesNovartis' Pasireotide

Chapter 8

Selected Emerging Immune-Based Therapies for Solid Tumors

8.1. Selected Active Immunotherapies and Vaccines in Development for CancerAdvantagene's ProstAtak

Agennix' Talactoferrin

Amgen's Talimogene Laherparepvec

Apeiron's APN311 (ch14.18/CHO) and APN301 (hu14.18-IL2)

Bavarian Nordic's PROSTVAC

Biothera's Imprime PGG

Cancer Advances' Polyclonal Antibody Stimulator (PAS)

Celldex Therapeutics' Rindopepimut

CEL-SCI's Multikine

Eisai's Farletuzumab

Endo Pharmaceutical's and Bioniche Life Sciences' Urocidin

Galena Biopharma's NeuVax

GlaxoSmithKline's GSK1572932A and GSK 2132231A

GSK1572932A

GSK 2132231A

immatics biotechnologies' IMA901

Merck Serono's and Oncothyreon's Stimuvax

NewLink Genetics' HyperAcute-Pancreas (algenpantucel-L)

NovaRx' Lucanix

Polynoma's POL-103A

Prima BioMed's CVac

RECOMBIO's Racotumomab (1E10)

Transgene's TG4010

United Therapeutics' ch14.18

Vaccinogen's OncoVAX

Vical's and AnGes' Allovectin-7

Wilex' RENCAREX

8.2. Selected Immunoconjugates in DevelopmentActive Biotech's ANYARA

Chapter 9

Selected Novel Cytotoxic Drugs in Development

9.1. BioNumerik Pharmaceuticals' Karenitecin

9.2. Celgene's and Dainippon Sumitomo Pharmaceuticals' Amrubicin

9.3. Cyclacel Pharmaceutical's Sapacitabine

9.4. Eleison Pharmaceuticals' Glufosfamide

9.5. Endocyte's Vintafolide (EC145)

9.6. Janssen Products', PharmaMar's, and Taiho's Yondelis

9.7. Spectrum Pharmaceuticals' and Allergan's EOquin (Apaziquone)

9.8. Taiho Pharmaceutical's TAS-102

9.9. Threshold Pharmaceuticals' TH-302

9.10. ZIOPHARM Oncology's Zymafos (Palifosfamide)

Chapter 10

Selected Other Emerging Therapies for Solid Tumors

10.1. Bayer's and Algeta's Alpharadin (Radium-223 Dichloride)

10.2. BioNumerik Pharmaceuticals' Tavocept

10.3. OncoGenex Technologies' and Teva Pharmaceutical Industries' Custirsen Sodium

10.4. Oncolytics Biotech's REOLYSIN

10.5. Steba Biotech's Tookad

Chapter 11

Business Considerations

11.1. Current Sales of Drugs for Treatment of Solid Tumors

11.2. Personalized Medicine in the Field of Solid Tumors

11.3. Selected Challenges and Hurdles Being Faced by Companies in the Field of Solid Tumors

Chapter 12

Expert Interviews

12.1. Thomas CK Chan, PhDChief Scientific Officer

ArQule

12.2. Habib Fakhrai, PhD Chief Scientific Officer

NovaRx

12.3. Michael G. Hanna, Jr., PhDFounder and Chairman

Vaccinogen

12.4. Spiro RombotisPresident and Chief Executive Officer

Cyclacel Pharmaceuticals

12.5. Vijay B. SamantPresident and CEO

Vical

References

Company Index

TABLES

Table 2.1. Incidence and Mortality of Selected Solid Tumors in the United States, 2011

Table 2.2. Five-Year Relative Survival Rates by Stage of Diagnosis (1999–2006) For Selected Major Cancers Targeted by Pharmaceutical Companies

Table 3.1. Selected Chemotherapy Drugs FDA-Approved for Treatment of Cancer (Most Are Available as Generic Drugs)

Table 3.2. Selected Drugs Approved By the FDA for Treatment of Brain Cancer

Table 3.3. Selected Drugs Approved By the FDA for Treatment of Breast Cancer

Table 3.4. Selected Drugs Approved By the FDA for Treatment of Cervical Cancer

Table 3.5. Selected Drugs Approved By the FDA for Treatment of Colorectal Cancer

Table 3.6. Selected Drugs Approved By the FDA for Treatment of Head & Neck Cancer

Table 3.7. Selected Drugs Approved By the FDA for Treatment of Non–Small-Cell Lung Cancer

Table 3.8. Selected Drugs Approved By the FDA for Treatment of Small-Cell Lung Cancer

Table 3.9. Selected Drugs Approved By the FDA for Treatment of Melanoma

Table 3.10. Selected Drugs Approved By the FDA for Treatment of Ovarian Cancer

Table 3.11. Selected Drugs Approved By the FDA for Treatment of Pancreatic Cancer

Table 3.12. Selected Drugs Approved By the FDA for Treatment of Prostate Cancer

Table 3.13. Selected Drugs Approved By the FDA for Treatment of Renal Cancer

Table 3.14. Selected Drugs Approved By the FDA for Treatment of Other Solid Tumors

Table 4.1. Selected Inhibitors of EGF Receptor Tyrosine Kinase Family

Table 4.2. Selected Inhibitors of the Ras-Raf-MEK-ERK Pathway

Table 4.3. Selected Inhibitors of c-Met

Table 4.4. Selected Inhibitors of Insulin-Like Growth Factor (IGF) and Insulin-Like Growth Factor Type 1 Receptor (IGF1R)

Table 4.5. Selected TGF-?2 Inhibitors

Table 4.6. Selected c-Kit Inhibitors

Table 4.7. Selected PARP (Poly [ADP-Ribose] Polymerase) Inhibitors

Table 4.8. Selected Inhibitors of the PI3K-Akt-mTOR Pathway

Table 4.9. Selected Other Emerging Therapies with Antiproliferative Effects

Table 5.1. Selected Emerging Therapies That Induce Apoptosis

Table 6.1. Selected Growth Factor Receptors and Their Ligands Involved in Angiogenesis

Table 6.2. Selected Angiogenesis Inhibitors That Target VEGFR, PDGFR, or FGFR

Table 6.3. Selected Angiogenesis Inhibitors That Target TIE Receptor and/or Its Ligands

Table 6.4. Selected Integrin Inhibitors

Table 6.5. Selected Other Angiogenesis Inhibitors

Table 6.6. Selected Vascular-Targeting/Disrupting Agents

Table 7.1. Selected Emerging Therapies with Anti-Androgen Activity

Table 7.2. Selected Other Emerging Therapies Targeting Regulation of Hormones

Table 8.1. Selected Emerging Immunotherapies, Immunomodulators, and Vaccines for Treatment of Cancer

Table 8.2. Selected Emerging Immunoconjugates for Treatment of Cancer

Table 9.1. Selected Emerging Cytotoxic Drugs in Development for Treatment of Cancer

Table 10.1. Selected Other Emerging Therapies for Solid Tumors

Table 11.1. Sales of Selected Drugs Used to Treat Solid Tumors

To order this report:

Pathology Industry: Therapies for Solid Tumors: Pipelines, Markets, and Business Considerations

Contact Nicolas: nicolasbombourg@reportlinker.com
US: (805)-652-2626
Intl: +1 805-652-2626

SOURCE Reportlinker



RELATED LINKS
http://www.reportlinker.com

More by this Source


Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

 

PR Newswire Membership

Fill out a PR Newswire membership form or contact us at (888) 776-0942.

Learn about PR Newswire services

Request more information about PR Newswire products and services or call us at (888) 776-0942.